China's medical products regulator approves Innovent Biologics's weight control injection
27/06/2025 08:34
BEIJING, June 27 (Reuters) - China's National Medical Products Administration has approved domestic drugmaker Innovent Biologics's 1801.HK weight control peptide injection's entry into the market, the regulator said in a statement on Friday. (Reporting by Beijing Newsroom; Editing by Muralikumar Anantharaman) ((yukun.zhang@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis